Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Clovis Oncology's share price for the quarter that ended in Sep. 2022 was $1.19. Clovis Oncology's Shares Outstanding (EOP) for the quarter that ended in Sep. 2022 was 144.8 Mil. Therefore, Clovis Oncology's market cap for the quarter that ended in Sep. 2022 was $172.3 Mil.
Clovis Oncology's quarterly market cap
declined
from Mar. 2022 ($290.6 Mil) to Jun. 2022 ($260.1 Mil) and
declined
from Jun. 2022 ($260.1 Mil) to Sep. 2022 ($172.3 Mil).
Clovis Oncology's annual market cap
declined
from Dec. 2019 ($573.2 Mil) to Dec. 2020 ($497.8 Mil) and
declined
from Dec. 2020 ($497.8 Mil) to Dec. 2021 ($349.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Clovis Oncology's Enterprise Value for Today is $624.5 Mil.
Clovis Oncology Market Cap Historical Data
The historical data trend for Clovis Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Clovis Oncology's Market Cap
For the Biotechnology subindustry, Clovis Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clovis Oncology's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clovis Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Clovis Oncology's Market Cap falls into.
Clovis Oncology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Clovis Oncology's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology (OTCPK:CLVSQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Clovis Oncology Market Cap Related Terms
Thank you for viewing the detailed overview of Clovis Oncology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Clovis Oncology (Clovis Oncology) Business Description
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLVSQ has been successfully added to your 